Women's health
Menopause Symptoms: What to Expect, What Stage You Might Be In, and What Helps
Menopause is the natural end of menstrual cycles, confirmed after 12 consecutive months without a period, usually in the late 40s or early 50s. Symptoms—hot flashes, night sweats, irregular periods, sleep problems, mood changes, and vaginal dryness—often begin years earlier, during perimenopause.
Talk to a clinician
Nina Osei, NP — Nurse Practitioner
checkups, refills & skin. Gale can match you with a licensed clinician for a visit.
Find care →What are the three stages: perimenopause, menopause, and postmenopause?
Perimenopause is the transition period — typically starting in the mid-to-late 40s, sometimes earlier — when hormone levels begin fluctuating. This is when most symptoms are at their most intense. Periods become irregular: more frequent, less frequent, heavier, lighter, or unpredictable. This phase can last anywhere from a few months to a decade, though a few years is most common.
Menopause itself is a single point in time: the day that marks 12 consecutive months without a period.
Postmenopause is everything after that point. Vasomotor symptoms (hot flashes, night sweats) often peak in perimenopause and the early postmenopausal years, then gradually ease — though for some people they persist longer. Genitourinary symptoms (vaginal dryness, urinary frequency, discomfort) often continue or worsen in postmenopause 1Ref 1American College of Obstetricians and Gynecologists (2022).The Menopause Years (Patient FAQ).Description of perimenopause, menopause, and postmenopause stages; vasomotor symptoms, night sweats, and genitourinary syndrome of menopause.
What causes the most common menopause symptoms?
Declining estrogen and progesterone levels affect many body systems:
Vasomotor symptoms. Hot flashes and night sweats — a sudden sensation of intense heat, often with flushing and sweating, lasting minutes — are the most recognized feature of the menopause transition. Night sweats are hot flashes during sleep and are a major driver of the sleep disruption many people experience in perimenopause 1Ref 1American College of Obstetricians and Gynecologists (2022).The Menopause Years (Patient FAQ).Description of perimenopause, menopause, and postmenopause stages; vasomotor symptoms, night sweats, and genitourinary syndrome of menopause.
Sleep disruption. Poor sleep independently worsens mood, memory, and energy, contributing to many of the cognitive and emotional symptoms of this phase.
Mood changes. Irritability, low mood, and anxiety are common and driven by both hormonal shifts and disrupted sleep. People with a prior history of depression or anxiety are at higher risk for mood episodes during this transition 2Ref 2O'Connor E, Henninger M, Perdue LA, et al. (2023).Screening for Depression and Suicide Risk in Adults: US Preventive Services Task Force Recommendation Statement.Importance of recognizing depression and mood symptoms in perimenopause; higher risk in people with prior history of depression.
Cognitive symptoms. Brain fog and difficulty concentrating are frequently reported and are typically temporary.
Vaginal and urinary symptoms. Vaginal dryness, reduced lubrication during sex, and urinary frequency or urgency — collectively called genitourinary syndrome of menopause — are driven by declining estrogen in local tissues and often worsen over time without treatment 1Ref 1American College of Obstetricians and Gynecologists (2022).The Menopause Years (Patient FAQ).Description of perimenopause, menopause, and postmenopause stages; vasomotor symptoms, night sweats, and genitourinary syndrome of menopause.
What are the less well-known symptoms of menopause?
Joint aches and stiffness are reported by many people during perimenopause and are thought to be related to changing estrogen levels, though they have many other potential causes. Heart palpitations are common in perimenopause and are usually benign — but should be evaluated to rule out cardiac causes, especially if frequent, prolonged, or accompanied by dizziness or chest pain.
Changes in skin texture, hair, and libido are frequently reported. Weight redistribution — particularly toward the abdomen — occurs even without significant total weight gain, related to changing hormone and insulin dynamics.
Bone density loss accelerates in the years around menopause, increasing longer-term risk of osteoporosis. Screening guidelines recommend bone density evaluation starting at age 65 for most people, or earlier if risk factors are present 3Ref 3US Preventive Services Task Force (2018).Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement.Bone density screening recommendation starting at age 65 (or earlier with risk factors); bone density loss accelerates around menopause.
What can help — from lifestyle adjustments to hormone therapy?
Many symptoms can be meaningfully reduced. Lifestyle approaches with evidence behind them include: regular aerobic and strength exercise (which reduces vasomotor symptoms and protects bone and muscle), cooling strategies for hot flashes (breathable clothing, fans, cold water), good sleep hygiene, and limiting alcohol and spicy foods — which trigger hot flashes in some people.
Menopausal hormone therapy (MHT, also called HRT) is the most effective treatment for vasomotor symptoms and also helps with sleep, mood, vaginal symptoms, and bone density. It is not right for everyone — it has risks and contraindications — but for many healthy people in the early postmenopausal years, the benefits outweigh the risks when considered in the context of a person's health history 4Ref 4Faubion SS, Crandall CJ, Davis L, El Khoudary SR, Hodis HN, Lobo RA, Maki PM, Manson JE, Pinkerton JV, Santoro NF, Shifren JL, Shufelt CL, Thurston RC, Wolfman W (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.Menopausal hormone therapy (MHT) as the most effective treatment for vasomotor symptoms; local vaginal estrogen for genitourinary syndrome; benefits vs. risks framework.
Non-hormonal options include certain antidepressants (used at lower doses for hot flashes) and other medications.
Local vaginal estrogen treats genitourinary symptoms with very low systemic absorption and is appropriate for many people who cannot or prefer not to use systemic hormones 4Ref 4Faubion SS, Crandall CJ, Davis L, El Khoudary SR, Hodis HN, Lobo RA, Maki PM, Manson JE, Pinkerton JV, Santoro NF, Shifren JL, Shufelt CL, Thurston RC, Wolfman W (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.Menopausal hormone therapy (MHT) as the most effective treatment for vasomotor symptoms; local vaginal estrogen for genitourinary syndrome; benefits vs. risks framework.
A clinician who is knowledgeable about menopause can help you weigh the options for your specific situation.
What tests might a clinician consider?
- FSH and estradiol — elevated FSH can suggest perimenopause or menopause; a single result is not definitive in perimenopause because levels fluctuate
- TSH — thyroid dysfunction is common in this age group and shares many symptoms with perimenopause
- Endometrial biopsy or pelvic ultrasound — recommended if postmenopausal bleeding, unusually heavy periods, or concerning bleeding patterns are present
- Bone density scan (DEXA) — recommended at age 65 or earlier with risk factors 3Ref 3US Preventive Services Task Force (2018).Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement.Bone density screening recommendation starting at age 65 (or earlier with risk factors); bone density loss accelerates around menopause
- Lipid panel and fasting glucose — cardiovascular risk increases after menopause; baseline metabolic screening is part of preventive care in this life stage
Common questions
How do I know if I am in perimenopause or if something else is causing my symptoms?
The classic picture — irregular periods, hot flashes, night sweats, and sleep disruption in someone in their late 40s — is strongly suggestive of perimenopause. But thyroid disease can produce nearly identical symptoms and is common in this age group. A clinician can order a TSH test and other relevant labs to sort this out. A clinical diagnosis is more reliable than a single hormone test, because levels fluctuate during perimenopause.
Is hormone therapy safe?
For many healthy people who are in early menopause and have no personal history of breast cancer, blood clots, or certain cardiovascular conditions, the benefits of menopausal hormone therapy for quality of life and bone health outweigh the risks. The type, dose, route, and duration all matter. This is a decision to make with a clinician who knows your full health history — not a one-size-fits-all answer.
Do hot flashes eventually go away on their own?
For most people, hot flashes are most intense in the early postmenopausal years and gradually ease over time. Some people experience them for only a few years; others continue to have them for a decade or longer. There is meaningful variation from person to person. If hot flashes are significantly affecting sleep or daily functioning, treatment options are available.
Should I be worried about bone health during menopause?
Bone density loss does accelerate around menopause because of declining estrogen. USPSTF guidelines recommend bone density screening starting at age 65 for most women, or earlier if there are risk factors such as smoking, low body weight, or a family history of osteoporosis. Regular weight-bearing exercise and adequate calcium and vitamin D intake support bone health during this transition.
Talk to a clinician
Nina Osei, NP — Nurse Practitioner
checkups, refills & skin. Gale can match you with a licensed clinician for a visit.
Find care →When to see a clinician promptly
- —Any vaginal bleeding after 12 consecutive months without a period (postmenopausal bleeding) — evaluate promptly; it is not assumed to be normal and can indicate endometrial changes
- —Heavy or prolonged irregular bleeding during perimenopause — warrants evaluation, not just waiting
- —Sudden onset of severe hot flashes or night sweats with unexplained weight loss, drenching sweats, or swollen lymph nodes — unusual pattern that needs evaluation
- —Chest pain, shortness of breath, or palpitations — should not be attributed to menopause without first ruling out a cardiac cause
This article provides general health information and is not a diagnosis. Changes in menstrual patterns — particularly any postmenopausal bleeding — should always be evaluated by a licensed clinician. This content does not replace a personalized clinical consultation.
References
- 1.American College of Obstetricians and Gynecologists (2022). The Menopause Years (Patient FAQ). ACOG Women's Health. link ✓Description of perimenopause, menopause, and postmenopause stages; vasomotor symptoms, night sweats, and genitourinary syndrome of menopause
- 2.O'Connor E, Henninger M, Perdue LA, et al. (2023). Screening for Depression and Suicide Risk in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. doi:10.1001/jama.2023.9297 ✓Importance of recognizing depression and mood symptoms in perimenopause; higher risk in people with prior history of depression
- 3.US Preventive Services Task Force (2018). Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement. JAMA. doi:10.1001/jama.2018.7498 ✓Bone density screening recommendation starting at age 65 (or earlier with risk factors); bone density loss accelerates around menopause
- 4.Faubion SS, Crandall CJ, Davis L, El Khoudary SR, Hodis HN, Lobo RA, Maki PM, Manson JE, Pinkerton JV, Santoro NF, Shifren JL, Shufelt CL, Thurston RC, Wolfman W (2022). The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. doi:10.1097/GME.0000000000002028 ✓Menopausal hormone therapy (MHT) as the most effective treatment for vasomotor symptoms; local vaginal estrogen for genitourinary syndrome; benefits vs. risks framework
4 sources, numbered by first appearance. General health information, not medical advice — synthetic demonstration content.